Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;87(1):64-9.
doi: 10.4269/ajtmh.2012.11-0817.

Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells

Affiliations

Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells

Enoche F Oga et al. Am J Trop Med Hyg. 2012 Jul.

Abstract

Antimalarials are widely used in African and Southeast Asian countries, where they are combined with other drugs for the treatment of concurrent ailments. The potential for P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) between antimalarials and P-gp substrates was examined using a Caco-2 cell-based model. Selected antimalarials were initially screened for their interaction with P-gp based on the inhibition of rhodamine-123 (Rho-123) transport in Caco-2 cells. Verapamil (100 μM) and quinidine (1 μM) were used as positive inhibition controls. Lumefantrine, amodiaquin, and artesunate all showed blockade of Rho-123 transport. Subsequently, the inhibitory effect of these antimalarials on the bi-directional passage of digoxin (DIG) was examined. All of the drugs decreased basal-to-apical (B-A) P-gp-mediated DIG transport at concentrations of 100 μM and 1 mM. These concentrations may reflect therapeutic doses for amodiaquin and artesunate. Therefore, clinically relevant DDIs may occur between certain antimalarials and P-gp substrates in general.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Screening for the inhibition of P-glycoprotein (P-gp)-mediated rhodamine-123 (Rho-123) transport by test antimalarials. Rho-123 (5 μM) was added to the basolateral side of a Caco-2 monolayer, and the basolateral-to-apical (B-A) transport of the tracer dye was measured at 120 min in the presence of test drugs (amodiaquin (ADQ), artemisinin (ASN), artesunate (ART), lumefantrine (LUM), artemether (ATM), chloroquine (CQ), and sulphadoxin (SDX)). Each antimalarial was used at a concentration of 1 mM. Verapamil (VER, 100 μM) and quinidine (QD, 1 μM) were used as the positive inhibition controls. Each column represents the mean ± SEM (N ≥ 3). *Significant difference, P < 0.05 versus control (transport in the absence of drugs).
Figure 2.
Figure 2.
Digoxin (DIG) transport kinetics. The bi-directional transport of DIG with or without verapamil (VER, 100 μM) across Caco2 cell monolayers was determined as a function of time. Each data point represents the mean ± SEM of four to seven replicate assays. Solid lines represent basolateral-to-apical (B-A) transport, and dashed lines represent apical-to-basolateral (A-B) transport.
Figure 3.
Figure 3.
Digoxin (DIG) and antimalarial drug kinetics. DIG transport across a Caco-2 cell monolayer was examined as a function of time. Apical-to-basolateral (A-B) transport and basolateral-to-apical (B-A) transport of DIG was investigated in the presence or absence of A, lumefantrine (LUM, 100 μM and 1 mM); B, amodiaquin (ADQ, 100 μM and 1 mM); and C, artesunate (ART, 100 μM and 1 mM). Each data point represents the mean ± SEM of at least four determinations. Solid lines represent basolateral-to-apical (B-A) transport, and dashed lines represent apical-to-basolateral (A-B) transport.

Similar articles

Cited by

References

    1. WHO . World Health Organization Expert Committee on Malaria. WHO, Geneva: 2000. http://www.rollbackmalaria.org/docs/ecr20.pdf 20th Report. Available at. Accessed April 28, 2011.
    1. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg. 2004;71:1–15. - PubMed
    1. Hay SI, Guerra CA, Tatem AJ, Atkinson PM, Snow RW. Urbanization, malaria transmission and disease burden in Africa. Nat Rev Microbiol. 2005;3:81–90. - PMC - PubMed
    1. Brentlinger P, Behrens C, Mice M. Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. Lancet Infect Dis. 2006;6:100–111. - PubMed
    1. Fehintola FA, Akinyinka OO, Adewole IF, Maponga CC, Ma Q, Morse GD. Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa. Curr Drug Metab. 2011;12:51–56. - PMC - PubMed

MeSH terms

Substances